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A B S T R A C T
Fatigue is often one of the most commonly reported symptoms in prostate cancer survivors, but it is also one of
the least understood cancer-related symptoms. Fatigue is associated with psychological distress, disruptions in
sleep quality, and impairments in health-related quality of life. Moreover, inflammatory processes and changes
related to the hypothalamic-pituitary-adrenal (HPA) axis and/or autonomic nervous system may also play a role
in cancer-related fatigue. Thus, effective treatments for fatigue in prostate cancer survivors represent a current
unmet need. Prior research has shown that Tai Chi Qigong, a mind-body exercise intervention, can improve
physical and emotional health. Herein, we describe the protocol of the ongoing 3-arm randomized controlled
Health Empowerment & Recovery Outcomes (HERO) clincal trial. One hundred sixty-six prostate cancer sur-
vivors with fatigue are randomized to a modified Tai Chi Qigong intervention (TCQ), intensity-matched body
training intervention (BT), or usual care (UC) condition. Guided by biopsychosocial and psychoneur-
oimmunology models, we propose that TCQ, as compared to BT or UC will: i) reduce fatigue (primary outcome)
in prostate cancer survivors; ii) reduce inflammation; and iii) regulate the expression of genes from two major
functional clusters: a) inflammation, vasodilation and metabolite sensing and b) energy and adrenergic acti-
vation. Assessments are conducted at baseline, the 6-week midpoint of the intervention, and 1 week, 3 months,
and 12 months post-intervention. If our findings show that TCQ promotes recovery from prostate cancer and its
treatment, this type of intervention can be integrated into survivorship care plans as the standard of care. The
study's findings will also provide novel information about underlying biobehavioral mechanisms of cancer-re-
lated fatigue.
Trial registration number: NCT03326713; clinicaltrials.gov.
1. Introduction
Prostate cancer is the most common malignant tumor among men in
the United States. Survival rates are high, with over 3.6 million men in
the U.S alive with this diagnosis. Over 90% of men are diagnosed with
local or regional prostate cancer, and the 5-year survival rate is 99%.
Prostate cancer develops mainly in older and in African American men
[1]. The median age at diagnosis is 66 years [2]. Both short- and long-
term treatment-related side effects are often compounded with age-re-
lated comorbidities and declines in physical, mental, and social
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functioning [3,4]. Moreover, many survivors have unique challenges
because they are coping with late and long-term effects of having had a
cancer diagnosis and treatment [3–6]. Together, these factors may in-
fluence their ability to engage in physical activity because of slower
post-treatment recovery, increased functional limitations, and other
quality of life (QOL) impairments.
Fatigue is one of the most commonly reported symptoms by cancer
patients at large, including men with prostate cancer [6–11]. Further-
more, it is one of the least understood cancer-related symptoms by
patients and healthcare providers [12]. Fatigue is associated with
psychological distress, disruptions in sleep quality, and impairments in
health-related QOL. Inflammatory processes and changes in the hy-
pothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system
may also play a role in cancer-related fatigue [13]. Many prostate
cancer patients report fatigue lasting 6 months or more after comple-
tion of treatment [14,15]. Fatigue is common, under-recognized, un-
dertreated, and leads patients to become more isolated, dependent on
others, and less physically active, and contributes to deconditioning,
which exacerbates fatigue [11,16–19].
Research on exercise interventions has shown benefits in treating
fatigue and improving QOL in cancer patients [20–25]. However, a
systematic review and meta-analysis of the effects of exercise in mod-
ulating cancer-related fatigue reported that only 11% of studies (n= 4)
enrolled prostate cancer survivors exclusively [26]. Recommendations
from the American Society of Clinical Oncology (ASCO) and the Na-
tional Comprehensive Cancer Network (NCCN) for the management of
cancer-related fatigue advise tailoring exercise interventions to the
tolerance of the individuals [11,27]. Limited published evidence exists
to inform health promotion survivorship guidelines for reducing fatigue
in men who have been diagnosed with and treated for prostate cancer
[28,29]. Indeed, most randomized controlled trials that have targeted
fatigue focused on breast cancer survivors [30,31]. Thus, there is a
relative absence of randomized efficacy trials that have focused on fa-
tigue symptoms as a primary outcome in men with prostate cancer
[32].
According to biopsychosocial models [33–35] and the field of psy-
choneuroimmunology [36–38], mind-body interventions promote ex-
ercise, relaxation and psychological well-being and may lead to sub-
stantial improvements in fatigue, distress, and QOL, along with
reductions of inflammation. Mind-body interventions have been de-
veloped for cancer patients during and following their medical treat-
ment. Data from these studies indicate benefits for physical and mental
aspects of health-related QOL [39–47] and are hypothesized to be as-
sociated with reductions in markers of inflammation [44]. Tai Chi Qi-
gong (TCQ) is one such mind-body intervention. TCQ differs from tra-
ditional exercise interventions by including a focus on deep breathing
techniques, synchronized and rhythmic movements, specific postures,
and meditation to induce relaxation [48,49]. It has been effectively
used in the elderly and medically-compromised populations, including
those with mobility limitations and cancer patients [48–54]. For pros-
tate cancer survivors suffering from fatigue, mind-body interventions
such as TCQ may be more appealing because they are not overly phy-
sically exertive and they are safe for elderly populations. In a small-
scale safety and feasibility randomized controlled trial, we found that
TCQ reduced fatigue and distress in inactive, elderly, prostate cancer
survivors [39]. However, these findings require replication in a larger
sample with evaluation of the durability of these effects.
The rationale for this study is that it will establish the efficacy of a
12-week manualized TCQ intervention for reductions in fatigue, the
primary outcome. Secondary outcomes include changes in the bio-
markers of inflammation, including genome wide transcriptional fac-
tors, and expression of fatigue-related genes. To date, no definitive
randomized controlled trial has studied the biological effects of Tai Chi
and/or Qigong compared to an exercise intensity-matched intervention
in fatigued prostate cancer survivors. Prior work has shown TCQ im-
proves physical and emotional health but research has not provided a
mechanistic understanding of the efficacy of TCQ on fatigue.
Inflammation is associated with fatigue, and mind-body interventions
influence cellular and molecular markers of inflammation, especially in
cancer survivors [55]. Furthermore, distinct functional clusters of genes
are associated with fatigue in men with prostate cancer. One cluster
includes genes related to inflammation and vasodilation/metabolite-
sensing and the other cluster is related to energy and adrenergic acti-
vation [56], which may represent different pathways by which TCQ
could reduce fatigue. The absence of definitive data on these outcomes
underscores the innovation, significance, and overall impact of the
present study.
2. Scientific rationale and conceptual framework
Biopsychosocial and psychoneuroimmunology models consider both
psychosocial and biological mechanisms. Psychological and social fac-
tors may interact and affect health and illness through neuroendocrine
(hypothalamic-pituitary-adrenal and sympathetic-adrenal-medullary
axes) and biologic (e.g., immune) pathways [33,36,37,57–59]. Mind-
fulness-based and light exercise interventions such as TCQ target stress
effector mechanisms. Such interventions can improve fatigue directly
and through effects on psychological distress and stress, social well-
being, QOL, physical well-being, and biological processes in cancer
survivors as delineated in Fig. 1 [42,48,52,55,59–63].
Basic research on neural-immune signaling indicates that pro-in-
flammatory cytokines can signal the central nervous system to generate
symptoms of fatigue and other behavioral and physical changes [64],
and there is growing evidence for a role of pro-inflammatory cytokines
in cancer-related fatigue [65]. Elevations in systemic, cellular, and
genomic markers of inflammation have been found in women with
breast cancer who experience persistent post-treatment fatigue
[66–68]. Prior randomized controlled trials have found that mind-body
interventions are associated with robust and sustained (i.e., one-year
follow-up) decreases in markers of systemic inflammation such as C-
reactive protein (CRP) and interleukin-6 (IL-6), decreases of TLR-4
stimulated production of pro-inflammatory cytokines, and decreases in
the expression of genes regulated by the transcription factor NFκB
[59,69–71]. Further, Tai Chi and Qigong are also associated with de-
creased blood pressure and cortisol [44,48,50–52,72,73]. While some
studies did not find effects of mind-body interventions on pro-in-
flammatory cytokines [46,73], a recent meta-analysis [55] showed that
Fig. 1. Study conceptual model.
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mind-body interventions reduce markers of inflammation such as CRP
and possibly IL-6, and reverse inflammatory gene expression profiles
[69,70]. Seemingly inconsistent findings that may be due to variation in
selection of the control condition [59,70,71], sample population, in-
tervention protocol and fidelity, control for confounding factors, and
length of treatment and follow-up, are addressed in this study design
[19,59,70,71]. Overall, available literature provides compelling evi-
dence that pro-inflammatory cytokines and the signaling pathways as-
sociated with inflammatory activation contribute to fatigue during and
particularly after cancer treatment [59,69–71]. However, the effects of
TCQ on these mechanisms in aging fatigued prostate cancer survivors
are unknown, further underscoring the significance of our study.
Although a growing body of work supports the role of inflammation
pathways as a biological mechanism associated with fatigue in cancer
patients and survivors, other work has suggested that multiple neural
and immune pathways may be involved [19,74]. It has been hypothe-
sized that the etiology of cancer-related fatigue likely involves the
dysregulation of several physiological and biochemical systems in-
cluding 5-HT neurotransmitter dysregulation, vagal afferent activation,
alterations in muscle and ATP metabolism, HPA axis dysfunction, cir-
cadian rhythm disruption, and cytokine dysregulation [75]. The spe-
cific fatigue-related neurological, energy metabolism and immune
pathways functionally altered by cancer, its treatment, and mind-body
therapies such as TCQ have not as of yet been established. Examining
the complex mechanisms of fatigue through leukocyte gene expression
(mRNA) allows multiple pathways to be examined efficiently from a
single peripheral blood sample. Testing of mRNA outcomes could
confirm these suggested genes as biomarkers for fatigue in prostate
cancer survivors and as genes that predict successful response to our
treatment (i.e., TCQ), including reductions in fatigue [39,74]. Genes
that track improvement could also be clues as to the mechanisms of
fatigue and the mechanisms of improvement caused by TCQ.
Applying a biopsychosocial and psychoneuroimmunology model to
TCQ in inactive, fatigued prostate cancer survivors, we hypothesize that
TCQ, as compared to an exercise intensity matched body training (BT)
or usual care (UC), will: (i) reduce fatigue (primary outcome); (ii) re-
duce inflammation as indexed by a vertically integrated approach:
systemic levels of pro- and anti-inflammatory cytokines, Toll-like re-
ceptor (TLR)-4 stimulated monocyte production of inflammatory cyto-
kines, inflammatory signaling (e.g., nuclear factor, NF-κB) and pro-
moter-based bioinformatics inflammatory transcriptional profiling; and
(iii) alter expression of two major fatigue-associated functional clusters
of genes: a) inflammation, vasodilation and metabolite sensing and b)
energy and adrenergic activation. We are also examining potential
underlying theoretical mediating factors (changes in distress, perceived
stress, sleep quality, functional and social well-being, physical activity,
inflammation pathway markers, and gene expression) and moderating
mechanisms (sociodemographic and clinical factors such as age and
receiving androgen deprivation/hormone manipulation therapy, body
mass index (BMI), and participation of a companion in intervention
classes) that are related to improvements in fatigue, which will further
specify and elucidate intervention effects.
If TCQ is proven effective, results of this trial can contribute to a
needed evidence base for prostate cancer survivorship care and be
broadly disseminated to a population who suffer extensively from fa-
tigue.
3. Study design and eligibility criteria
This 3-arm, parallel arm, randomized superiority clinical trial ad-
heres to the CONSORT guidelines for conducting and reporting clinical
trial results [76]. The study design and CONSORT diagram are depicted
in Fig. 2 and the inclusion and exclusion criteria are delineated in
Table 1. After obtaining written informed consent and baseline as-
sessments, 166 fatigued prostate cancer survivors age 55 years and
older are randomized to the TCQ arm, BT arm, or UC arm. Patient-
reported assessments (surveys) occur at baseline (within 1-week pre-
intervention), mid-intervention (6 weeks), 1-week post-intervention
(13 weeks), and at 3 months and 12 months post-intervention. Phle-
botomy for biomarker assessment occurs at baseline, 13 weeks, 3
months, and 12 months post-intervention.
3.1. Recruitment and retention
Prostate cancer survivors are identified and recruited through a
variety of sources in New Jersey (NJ) and New Mexico (NM): 1) in-
vitation letters to prostate cancer patients and clinician referrals from
health care providers; 2) face-to-face clinic-based recruitment; 3)
community-based recruitment strategies (e.g., radio, newspaper, and
flyers) and 4) cancer registries.
As a recruitment and retention strategy we permit participants to
have a social network member (e.g., family member/caretaker/sig-
nificant other) accompany them to classes as was done in our feasibility
trial [39]. We will evaluate this possible design effect in the analysis
(although we did not observe appreciable subgroup differences in our
feasibility trial). Several additional strategies are used to promote re-
tention and adherence to the interventions: 1) Project staff meet and
greet each participant before classes and collect/distribute study-re-
lated surveys and logs/diaries; 2) weekly phone calls to non-adherent
participants to promote adherence with motivational strategies and
barriers counseling; 3) reminder postcards, email, text messages, and/
or letters are sent to participants about appointments or class schedules
based on participants’ preferences; 4) monetary incentives (in the form
of pre-paid merchandise cards: $50 per completion of each assessment
at baseline, mid-point, and 1-week, 3-month and 12-month post inter-
vention classes and an additional $100 for completion of all of the as-
sessments for up to $350 in total per participant; 5) continued emphasis
on the importance of the study at the beginning or end of classes; and 6)
class instructors emphasize the importance of attendance for personal
benefit and the scientific integrity of the study at the end of each class.
3.2. Randomization and blinding
For participant recruitment and research materials such as the
participant consent forms, recruitment letters, advertisements, assess-
ments, and intervention implementation, we avoid the use of the terms
Tai Chi and Qigong specifically. Instead, we refer to the intervention
groups as follows: TCQ intervention is referred to as body-mind training
(BMT) and the intensity-matched condition is referred to as body
training (BT). This is done to help to reduce bias by minimizing parti-
cipants’ expectations or perceived differences between the groups.
After obtaining informed consent and baseline assessments, 166
eligible men are randomized by using computer-generated random
numbers with an allocation ratio of 2:2:1 to the TCQ, BT, or UC arms,
respectively. Participants are instructed not to discuss their arm as-
signment with study personnel during their assessments; questionnaires
are self-administered. The study investigators, biostatisticians, and the
biometric testing and lab technicians are blinded to intervention allo-
cation. The technicians who analyze biospecimens are blind to all other
data. Recruitment documents, screening materials, and informed con-
sent indicate that the purpose of this study is to evaluate the effects of
two types of light exercise on well-being. Thus, participants are not
blinded to the condition to which they are assigned, but they are not
informed of the specific study hypotheses. Potential therapeutic benefit
in general terms (improvements in well-being) of the interventions is
discussed equally and with equal confidence by study staff and in-
structors to support retention of participants and control expectancy
effects [77].
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3.3. Study arms
3.3.1. Tai Chi Qigong
TCQ provides a unifying, short-hand label for the many types of
Qigong and Tai Chi (including Tai Chi Chih) that have been used, as
these practices have similar theoretical foundations, proposed me-
chanisms of action, and expected benefits [52]. The intervention in-
cludes Tai Chi practices with a primary Qigong focus, and most Qigong
has a Tai Chi component. The different types of TCQ vary in the amount
of Qigong (i.e., relatively static moves making them generally simple to
perform) vs. Tai Chi (i.e., dynamic moves that can take months to learn,
years to master, and are more cognitively demanding). Hence, we have
manualized a TCQ intervention that incorporates Qigong and simplified
forms of Tai Chi (e.g., Tai Chi Ruler, Cloud Hands and Wild Goose).
These manualized TCQ movements and postures can be learned rela-
tively quickly because they involve repeating a single movement or
Fig. 2. Proposed Study Design and CONSORT Diagram showing the flow of participants and anticipated numbers at each stage.
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small number of movements. They can be done seated or standing.
Further, TCQ is very adaptive to different levels of physical functioning,
making it well suited for inactive senior men with prostate cancer and
fatigue [48].
The TCQ sessions are led by instructors who have prior training in
TCQ, and training in the project's manualized TCQ intervention. During
the first session, the instructor explains the underlying TCQ theory and
orients participants to the procedures of TCQ. In all subsequent group
sessions, participants practice TCQ under the instruction of a TCQ in-
structor. The rationale that is communicated to participants rando-
mized to this arm is that TCQ is a health promotion intervention that
incorporates meditation, body training, and repetitive movements to
promote health and well-being. Each session includes: 1) warm up and
a review of TCQ principles; 2) meditation with TCQ movement; 3)
breathing techniques; and 4) relaxation procedures. Eccentrically-
biased movements that can be completed while seated or standing
(depending on participants ability) were chosen for the intervention
(e.g., rocking chair, Tai Chi ruler, etc.) to increase the intensity of the
intervention while maintaining a level of safety [83]. The classes last
60 min, take place twice per week, and are supplemented with home-
based practice by using an instructional DVD and handouts delineating
the specific poses to help with their independent practice. The TCQ
manual and handouts for home practice are included in the supple-
mental materials. Participants are instructed to practice at least 30min
per day, at least 3 days per week throughout the intervention and post-
intervention follow-up period.
3.3.2. Body training
The rationale for the BT condition is that it will serve as a move-
ment-based, intensity/volume-matched and attention-matched control
arm. It matches the TCQ classes in non-specific factors such as contact
time, getting out of the home at least twice per week, experiencing a
therapeutic environment, interactions with trained instructors and
other research participants, attention, and expectation of therapeutic
benefit. In addition, this intervention controls for flowing, stretching
(e.g., extending arms upward and outward) and eccentric (e.g., bending
and lowering) movements, and home practice with a DVD. The ther-
apeutic benefit of participation in this arm is emphasized by both study
staff and the instructor to support retention of participants and control
expectancy effects [77]. The rationale communicated to participants is
that this exercise program incorporates repetitive movements to pro-
mote health and well-being. Like the TCQ classes, the 60-min exercise
classes will meet twice per week for 12 weeks, and participants will be
provided with an instructional DVD and handouts delineating the
specific movements to help with their independent practice, and given
the same expectations for home practice (minimum of 3 days per week).
As with the TCQ classes, BT classes begin within two weeks after the
baseline assessment.
The BT program was developed by two exercise specialists (F.A. and
E.H.) with previous experience designing exercise-training programs.
Initially, the TCQ program was presented to the two professionals and
they designed the exercise program simulating the TCQ movement
pattern in muscle action (eccentric, concentric and isometric), posture
(seated or standing), number of sets and repetitions. After the devel-
oping the BT program, a preliminary study was conducted with healthy
individuals performing one session of TCQ and BT. The oxygen con-
sumption through indirect calorimetry (Parvomedics, Trueone 2400,
Sandy, Utah) heart rate Polar M400 (Polar Electro Oy, Kempele,
Finland), and rate of perceived exertion using the Borg Rating of
Perceived Exertion Scale [84] were measured. No differences were
found between the TCQ and BT sessions.
3.3.3. Usual care
Participants in the UC arm receive care as normal and do not attend
classes. However, they are asked to complete the same assessments as
participants in the TCQ and the BT classes.
3.4. Standardization and intervention fidelity
For all classes, instructors and study staff who observe each class
complete intervention fidelity checklists to ensure that the intervention
is being administered as intended according to the intervention man-
uals and study protocol. To assess the perceived intensity of the two
exercise interventions, self-reported Borg Rating of Perceived Exertion
(RPE) scale measures [84] are collected following every class session
for 24 time points. The completed scales are reviewed by the study team
bi-weekly to ensure that both interventions are similar with regard to
being intensity-matched.
3.5. Study assessments and measures
The timing of assessments is delineated in Table 2.
3.6. Outcome measures
Fatigue: Fatigue, the primary outcome of the study, is assessed with
the Functional Assessment of Chronic Illness (FACIT)-Fatigue Scale
[85], is often used with cancer survivor populations. This 13-item scale
assesses level of fatigue during usual activities over the past 7 days,
with higher scores indicating less fatigue (score range=0–52; Cron-
bach's alpha=0.86).
Psychological Distress, Sleep, Perceived Stress, Well-Being and
QOL: We will also examine whether intervention effects might extend
to behavioral symptoms and health-related measures associated with
fatigue and serve as mediators of these effects. We will assess: 1) psy-
chological distress (depression and anxiety) using the Brief Symptom
Inventory-18 (BSI-18; α=0.79–0.91) [86]; 2) stress perceptions using
the Perceived Stress Scale (α=0.78) [87]; 3) sleep quality and amount
by using the Pittsburgh Sleep Quality Index (α= .83) [88] and the
Berlin Sleep Questionnaire [89] and Consensus Sleep Diary [90]; 4)
social well-being with validated PROMIS 2 Version 2 measures: SF4a
Satisfaction with Participation in Social Roles and activities, SF4a
Emotional Support, SF4a Ability to Participate in Social Roles, and SF4a
Social Isolation [80]; 5) functional well-being with the Functional Well-
being Scale [91]; 6) health-related quality of life (mental and physical)
using the SF-36v2™ Health Survey [78]; and 7) spirituality using the
Table 1
Eligibility criteria.
Inclusion Criteria
Age ≥55 years
Previous or current diagnosis of local, regional, or metastatic prostate CA
Chemotherapy, radiation therapy and/or surgery completed 3≥months ago and/or
on ADT/Hormone manipulation ≥4 months
Fatigue: SF-36 Vitality Scale score of≤13 [78,79] or PROMIS Fatigue Scale score of
≥9 [80]
Live≤ 75 miles of New Brunswick
Inactive (< 150min of moderate intensity exercise/week within past 3 months)
Has transportation and is willing to attend on-site classes and assessments
Exclusion Criteria
Prostate CA metastasis to liver, brain or lung OR diagnosis of other cancer (except
non-melanoma skin CA/CA free≥ 5 years)
Patient Health Questionnaire PHQ-9 score > 12 indicating moderate to severe
depression and/or indication of suicidality from response to PHQ-9 [81]
Karnofsky performance status score≤ 50 [82]
Non-ability to consent/Non-English proficient
Mind-body intervention is a current regular practice within 12 months (2–3 times a
week of uninterrupted practice over 2 months)
Severe respiratory, cardiovascular, or neurological problems
Myalgic Encephalomyelitis/Chronic fatigue syndrome, current major depression,
alcohol use disorder, shift work
Currently receiving some chemotherapy agents (VePesid, Cytoxan) or
radionucleotides (Strontium-89, Samarium (Quadramet®), Radium-223 (Xofigo
®)) & some other therapies
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FACIT-Sp-12 Spiritual Well-Being Scale [92,93]. Follow-up questions
will be asked of all participants at 1-week post intervention. These
questions are to briefly assess their experience during the intervention
period.
Clinic Physical Assessments: Participants are asked to attend ap-
pointments at the two study sites (in New Jersey or New Mexico) at
baseline, and at one week, three months, and 12 months post-inter-
vention. During these appointments, participants receive a brief phy-
sical assessment that includes blood pressure, height, weight, waist/hip
circumference measurements, heart rate variability, a 6-min walk test,
the Timed Up and Go (TUG) test [94], and a chair stand test. These
appointments coincide with the collection of biospecimens and collec-
tion of surveys by study staff.
Inflammation Biology Measures and Fatigue-Related
Functional Cluster Gene Expression: Blood specimens for inflamma-
tion biology and gene expression measures are collected at the study
enrollment sites, prepared and shipped to the Cousins
Psychoneuroimmunology Center at the University of California Los
Angeles (UCLA) for laboratory analysis by using methods found to be
highly reliable [59,69–71]. Our pilot work identified differentially ex-
pressed genes associated with fatigue in prostate cancer patients com-
pared to healthy controls [74]. These genes are grouped into two major
functional gene clusters by mRNA level intercorrelations: 1) In-
flammation, Vasodilation, and Metabolite Sensing and 2) Energy and
Adrenergic Activation. To test the hypothesis that genes within these
defined functional clusters are affected by TCQ and associated changes
in fatigue, we will target our analysis of gene expression for these
biomarkers. Following these a priori tests, we will examine expression
of additional genes/pathways from the full genomic data yielded by the
gene expression assays. Stool is collected and processed for gut mi-
crobes (microbiome analysis), including DNA and RNA sequencing. The
stool samples are stored for future research. A 3-day food diary and a
full food frequency questionnaire are collected for future analyses.
3.7. Covariates, moderators, and mediators
Participants complete demographic questions, including self-re-
ported age, race, ethnicity, income, education level, stage of diagnosis,
types of cancer treatment, date of diagnosis, and date of primary cancer
treatment. Comorbidity, BMI, and other medication information is
collected at each survey time point, including current prescription and
non-prescription medications and over-the-counter supplements. Body-
mass index (BMI) and heart rate variability is assessed during the
phlebotomy visits. Physical activity outside the intervention is assessed
at all survey time points with the Godin-Shephard Leisure-Time
Physical Activity Questionnaire [95] and the Measurement of Older
Adults Sedentary Time (MOST) Questionnaire [96]. In addition, parti-
cipant activity levels throughout the intervention period are recorded
with weekly activity logs of home performance of the interventions and
other forms of physical activity. The log includes a measurement of
perceived exertion using the Borg scale for each activity performed and
the number of times a specific activity was performed [84].
Participants are also asked to wear a pedometer and are trained on
how to use it to record the number of steps they take each day [97].
Activity and home practice logs are collected once a week at class
check-in and at the 3-month and 12-month follow-ups. At the end of the
12-week intervention, participants are encouraged to continue practi-
cing what they learned during their classes (TCQ and BT), ideally 5
times a week, by using the DVDs provided to them. UC participants are
asked to continue with their normal daily activities. All participants are
also asked to turn in weekly logs to capture activity and capture fre-
quency and duration of engagement (DVD, handouts, and non-aerobic
exercise and Borg scale) for their respective assigned study arm. UC
participants are called weekly by study staff to collect their activity log
and pedometer readings because they will not attend classes. Logs are
collected once a week at class check-in, or by telephone and at the 3-
month and 12-month follow-up. After the 13-week follow-up, TCQ and
BT arm participants receive monthly mailed reminders, phone calls,
text messages, or other social media contact (as preferred by each in-
dividual participant) to continue their home practice. They are asked to
report the average frequency of their home practice and exercise fre-
quency at the 3- and 12-month follow-up assessments.
Treatment credibility and expectations are assessed during the first
week of class, mid-intervention and post-intervention by using the 6-
item Credibility/Expectancy Scale modified for a class-based interven-
tion with health and well-being as outcomes [98]. This scale assesses
both expectancy and credibility factors and includes items about
thoughts and feelings of each individual participant about the like-
lihood that the intervention will have the desired effect (i.e., on health
and well-being), and expectations about the size of the effects. Across
several treatment populations the scale demonstrated high internal
consistency (α=0.79–0.81) and high test-retest reliability (0.75–0.82)
[98].
3.8. Data accuracy and protocol compliance
Several strategies are used to assure data accuracy and protocol
compliance. The database uses logic and range checks to minimize data
entry errors. Double data entry strategies are used to detect data entry
errors. The project coordinator and database manager regularly assess
for errors and generate reports to discuss data entry accuracy and
quality improvement measures. Completion of surveys and blood draws
is monitored by study staff. Intervention fidelity checklists and parti-
cipant intervention logs are used to assess whether the interventions
were implemented as intended and the level that participants are en-
gaging in home practice.
3.9. Sample size and power calculations
The primary goal of the statistical analyses is to assess the efficacy of
the TCQ intervention in reducing fatigue (primary outcome), compared
to the BT and UC arms. To assess both short-term and long-term in-
tervention effects, fatigue is measured at baseline, followed by four
additional measurements: 6 weeks as an interim, 13 weeks, and 3- and
12-months post-intervention. We will use a 2:2:1 allocation ratio (TCQ,
BT, and UC, respectively) and a repeated measures design (1 between
factor for intervention group and 1 within factor for time) for a total of
123 subjects (49, 49, 25 subjects for TCQ, BT, and UC groups,
Table 2
Timing of participant assessments.
Assessment Baseline 6 weeks 13 weeks 3 months 12 months
Informed Consent X
List of Medications X X X X X
Survey X X X X X
Sleep Diary (7 days) X X X X X
Food Diary (3 days) X X X X
Food Frequency
Questionnaire
X
Stool X X X X
Clinical Measures:
Height, weight,
blood pressure,
hip:waist ratio
X X X X
Heart Rate Variability X X X X
Biospecimen Collection X X X X
Timed Up & Go (TUG)
Test
X X X X
6-min Walk Test X X X X
Chair Stand Test X X X X
Credibility/Expectancy
Questions
X X X
Satisfaction Questions X
Adherence Questions X X
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respectively). In our TCQ feasibility trial [39], we found an average
fatigue score for the target population of 32.4, a standard deviation of
8.5, and an autocorrelation between adjacent measurements on the
same subject of 0.7. We assume that first-order autocorrelation (AR1)
adequately represents the autocorrelation pattern. We assume the
group average fatigue score means of 39.9, 34.4, and 32.4 after the
immediate post-intervention (3 months post-intervention), reflecting a
23%, 6%, and 0% increase (improvement) in fatigue score for TCQ, BT,
and UC, respectively. We will have at least 80% power to detect a
minimum of 15% difference in fatigue score among the study arms to
test group by time interaction factors by using a Hotelling-Lawley Test
[99] with a 2.5% significance level and an actual effect size of 0.3, 0.45,
and 0.46 for group, time, and interaction, respectively. The Hotelling-
Lawley test includes adjustment for Type I error at 2.5%. Based on t-test
evaluation, group sample sizes of 40 and 20 achieve 81% power to
reject the null hypothesis of equal means when the population mean
difference is 7.5 (39.9 vs. 32.4 post-intervention) with a standard de-
viation for both groups of 8.5 and with a significance level of 0.025
using a two-sided two-sample equal-variance t-test [100–102]. The
group sample sizes are inflated to account for 25% attrition. Thus, 166
participants will be randomized to the three arms, with 66 receiving
TCQ, 66 receiving BT, and 34 receiving usual care.
Noncompliance and missing data will be handled by intention-to-
treat (ITT) analysis for the primary and secondary outcomes. To
manage missing data, multiple imputation under the Missing at
Random assumption will be applied using a Markov Chain Monte Carlo
method [103,104] via PROC MI in SAS, given the expected pattern of
non-monotonic missing data. A post hoc approach [103] will address
the influence of Missing Not at Random (MNAR) on fatigue. Sensitivity
analyses will be performed to assess alternative multiple imputation
techniques upon the extent of MNAR influences.
3.10. Data analysis
The analytical goal of the primary outcome analysis is to test if a
TCQ intervention will reduce fatigue in inactive, older prostate cancer
survivors, compared to exercise or UC. The primary outcome for this
study is fatigue as measured by the FACIT [91]. Generalized linear
mixed effects model (GLMM) with an appropriate link function (e.g.,
identity for continuous and logit for binary outcomes) will be fitted to
examine the effects of the intervention assignment on the longitudinally
measured primary outcome (at baseline, 6 weeks, 13 weeks, and 3- and
12-months post intervention) with the main covariates of intervention
condition, time (in weeks), and their interaction between condition and
time. The interaction term will be the main test of interest as it tests for
the average departure from the slope due to the intervention. The po-
tential correlations within the same subjects due to the repeated mea-
surements will be accounted for in the GLMM by using unstructured,
AR(1) or compound symmetric correlation structures. If baseline values
of potential confounders (e.g., medications, BMI, age, stage, prior
treatment, co-morbidities, psychosocial factors, presence of a compa-
nion and companion dose) are not balanced across the 3-study arms,
their influence on outcomes of interest will be assessed by adjustment in
multivariable models. We will explore intervention effects on patient-
reported outcomes 12 months after completion of the group classes.
Analysis of secondary outcomes, include the hypotheses that TCQ will
decrease biomarkers associated with inflammatory mechanisms such as
serum levels of CRP, IL1, IL6, IL8, IL10, and TNF, decrease TLR-4 sti-
mulated production of inflammatory cytokines (all baseline, 13-week,
and 3-month specimens), and decrease expression of several genes
regulated by NF-κB pathways (all baseline and 13-week specimens).
GLMM with L1-Penalized Estimation (LASSO method) [105,106] for
variable selection will handle each of the biomarkers with the main
covariates of intervention conditions, time, and their interaction be-
tween condition and time, as described above. We will also test the
hypothesis that TCQ versus exercise and UC, will regulate the
expression of genes from two major functional clusters: 1) inflamma-
tion, vasodilation and metabolite sensing and 2) energy and adrenergic
activation. Descriptive statistics will be summarized for each gene at
baseline and 1-week post intervention (Week 13) and for the change
over time by intervention arms. Then, general linear model/ANOVA or
the corresponding non-parametric methods will be used to determine
the difference in each gene expression across arms. For the separate
functional clusters, GLMM will be utilized, while accounting for the
correlation among the genes within the cluster by including a random
effect of gene and specifying a correlation structure. Multiple compar-
isons adjustment will be done by using the false discovery rate (FDR)
method.
To explore the impact of potential mediators and moderators of
TCQ's effect on fatigue, we will use multiple generalized linear re-
gression models. Specifically, based on the pattern of observed results
and the study's conceptual model depicted in Fig. 1, mediation analysis
[107] will be conducted to examine whether psychosocial (changes in
distress, perceived stress, sleep, mental QOL, physical QOL, social well-
being, functional well-being, presence of a companion) and/or biolo-
gical mechanisms (inflammation biology pathways, treatment ex-
pectations, fatigue-related gene expression) mediated or explained in-
tervention effects on the fatigue outcome. Adjusted analysis for all aims
will control for these factors and will also control for dose (physical
activity level, class attendance level, dose of home practice, and dose of
companion involvement) as well as sociodemographics and clinical
factors. Path coefficients for the mediator model and 95% bootstrap
confidence intervals for effects will be estimated to determine the sta-
tistical significance of a potential mediator [107]. Further investigation
with possible exposure-mediator interactions and causal interpretation
will be investigated by using VanderWeele methods [108]. Subgroup
analyses (e.g., age<75 vs. ≥75, companion participation, co-mor-
bidity index, ADT/hormone manipulation treatment status, and inter-
vention dose) will be conducted as sensitivity analyses for the primary
and secondary outcomes. All subgroup and interaction analyses will be
interpreted cautiously as the Type I error rates are unknown.
4. Ethical considerations
All participants are given information about the study and an op-
portunity to ask questions. Before obtaining written informed consent,
all participants are provided with an explanation of 1) the purpose of
the study; 2) randomization process; 3) the use of data and procedures
for ensuring confidentiality; 4) voluntary participation and the right of
the participant to withdraw from the study at any time; and 5) potential
harm that could occur as a result of participation. Informed consent is
obtained before any study measurements. The study has been approved
by the institutional review boards at Rutgers University (The State
University of New Jersey) and the University of New Mexico. Trial re-
gistration number: ClinicalTrials.gov Identifier: NCT03345563; Date
registered: November 17, 2017.
5. Discussion
This 3-arm randomized clinical trial will determine the efficacy of
TCQ for reducing fatigue in prostate cancer survivors and examine in-
flammatory biology and selected gene-expression pathways hypothe-
sized to contribute to the intervention's effect. Rigorous clinical trials
with activity-matched and usual care control groups are needed to as-
sess whether TCQ is a specific and efficacious intervention for fatigue in
this cancer survivor population. Our study will fill this knowledge gap.
Additionally, examining inflammatory biology and gene expression
outcomes relevant to fatigue and other key symptoms that cluster with
fatigue is a clinically meaningful and novel direction, as this trial will
provide an unprecedented opportunity to explore TCQ's effect at the
cellular and molecular level.
The impact of this trial is underscored in several important ways.
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First, despite the increasing and large numbers of prostate cancer sur-
vivors living with increasing disease burden and/or treatment-related
impairments to their quality of life, there is limited evidence regarding
interventions targeting fatigue in this population. Research on mind-
body interventions to improve patient-reported symptoms and quality
of life is much less frequent for prostate and senior cancer survivors
than breast cancer survivors [109,110] and to our knowledge, no de-
finitive randomized controlled trials have studied the effects of a TCQ
intervention in fatigued prostate cancer survivors. Our study addresses
this knowledge gap and the findings will provide decision-makers and
practitioners with information needed to make evidence-based deci-
sions and recommendations regarding the management of cancer-re-
lated fatigue.
Second, we utilize a 3-arm randomized design with both a UC and
an intensity-matched, exercise condition. Outcome differences between
the TCQ and UC conditions will provide an estimate of the efficacy of
the TCQ intervention for improving fatigue. In addition, we will com-
pare TCQ to the BT condition, consisting of intensity-matched non-TCQ
and eccentric movements, but no meditation or focused deep breathing,
to determine the benefits of these relaxation components above the
effects of exercise, and social support and other salient non-specific
factors (same dose of class attendance, attention by study staff and
instructors, social setting) that could influence outcomes.
Third, a growing body of literature supports the use of mind-body
interventions for treatment of fatigue in individuals with cancer and
reduction of biological markers of inflammation related to fatigue
particularly for breast cancer patients. It is unknown whether the fa-
tigue, psychological distress, sleep impairments, and quality of life/
well-being prevalent in aging prostate cancer survivors
[16,21,111–113] will be as responsive to TCQ interventions. We have
shown that the TCQ intervention is well-tolerated and acceptable by
elderly, fatigued prostate cancer survivors [39], but a larger efficacy
clinical trial such as ours is required before this intervention can be
recommended as part of survivorship care plans.
The importance of this study is further underscored by using both an
unprecedented discovery and targeted approach to identify the biolo-
gical pathways involved in inflammation biology associated with fa-
tigue in aging, fatigued prostate cancer survivors practicing TCQ. We
will examine the inflammatory signaling changes that result from TCQ
practice, and genome-wide transcriptional factors to determine if they
are plausible candidates for molecular mediators of inflammation and
glucocorticoid receptor-related signaling pathways that may underlie
increased inflammatory signaling related to fatigue. Last, we are just
beginning to understand how gene expression relates to the fatigue
experienced by cancer survivors. Recent work has identified two
functional gene clusters (i.e., 2 distinct pathways) that are correlated
with the level and severity of fatigue experienced by prostate cancer
patients [74]. Coupling a TCQ intervention with patient-reported fa-
tigue and gene expression measurement pre- and post-intervention in
fatigued men with prostate cancer will allow a better understanding of
the causal role of gene expression in fatigue in this patient population.
In summary, a TCQ intervention may be of great benefit for fatigued
and inactive prostate cancer survivors because it is of relatively low
intensity, acceptable, convenient, and it can be practiced from a seated
posture or standing. Its safety, preliminary efficacy, clinical implica-
tions, and low cost make this an attractive intervention for this survivor
population. The study's findings will provide novel information about
underlying biobehavioral mechanisms as well as novel and needed data
to inform evidence-based recommendations for survivorship care.
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